Raffaella Magrassi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Raffaella Magrassi has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Cristiana Picco
Istituto di Biofisica, Consiglio Nazionale delle Ricerche, 16149 Genova, Italy
1 shared publication - Federica Viti
Institute of Biophysics, National Research Council, Genoa, Italy
1 shared publication - Francesco Balestra
Laboratory of Molecular Medicine, National Institute of Gastroenterology “S. de Bellis”, IRCCS Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy
1 shared publication - Ludovica Cacopardo
Research Centre E. Piaggio, University of Pisa Pisa Italy
1 shared publication - Maria De Luca
Laboratory of Molecular Medicine, National Institute of Gastroenterology, IRCCS “S. de Bellis” Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy
1 shared publication - Maria Grazia Faticato
IRCCS Gaslini
1 shared publication
Latest Publications
- Open Access
- 21 March 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (3) , 431
Targeting the Gut: A Systematic Review of Specific Drug Nanocarriers
The intestine is essential for the modulation of nutrient absorption and the removal of waste. Gut pathologies, such as cancer, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), and celiac disease, which extensively impact gut functions, are thus critical for human health. Targeted drug delivery is essential to tackle these diseases, improve therapy efficacy, and minimize side effects. Recent strategies have taken advantage of both active and passive nanocarriers, which are designed to protect the drug until it reaches the correct delivery site and to modulate drug release via the use of different physical–chemical strategies. In this systematic review, we present a literature overview of the different nanocarriers used for drug delivery in a set of chronic intestinal pathologies, highlighting the rationale behind the controlled release of intestinal therapies. The overall aim is to provide the reader with useful information on the current approaches for gut targeting in novel therapeutic strategies.
- 21 March 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (3) , 431
Open AccessTargeting the Gut: A Systematic Review of Specific Drug Nanocarriers
The intestine is essential for the modulation of nutrient absorption and the removal of waste. Gut pathologies, such as cancer, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), and celiac disease, which extensively impact gut functions, are thus critical for human health. Targeted drug delivery is essential to tackle these diseases, improve therapy efficacy, and minimize side effects. Recent strategies have taken advantage of both active and passive nanocarriers, which are designed to protect the drug until it reaches the correct delivery site and to modulate drug release via the use of different physical–chemical strategies. In this systematic review, we present a literature overview of the different nanocarriers used for drug delivery in a set of chronic intestinal pathologies, highlighting the rationale behind the controlled release of intestinal therapies. The overall aim is to provide the reader with useful information on the current approaches for gut targeting in novel therapeutic strategies.